- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06014125
Paramedical Tele-education on Moderate Depressive Episodes (TE-DSP)
Tele-education in Patients With a Moderate Depressive Episode in Primary Care
Considering that one out of five people may experience depression during the course of their life, and that compliance to anti-depression medication is often not optimal.
Psycho-educational interventions are recommended in international clinical practice guidelines for the management of depression. They are the first step in the treatment protocol.
Psychoeducation in the treatment of depressive episodes has been shown to be an effective intervention because it reduces depressive symptoms, the risk of relapse or recurrence and improves adherence to treatment.
In France, there are only one approved psycho-education programme, but it concerns a population of patients under psychiatric care.
No psycho-education programme has yet been carried out or evaluated in France on depressed patients followed up in primary care by their General Practitioner.
Recent changes in our healthcare practices, which have required adaptation to the pandemic context, have led to the development of the use of telemedicine.
This study aims to evaluate a new and 100% remote educational program adapted to patients ongoing moderate depression and focused on medication adherence, economic gain and patients and professional satisfaction.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In addition to the usual standard care, recruited patients will benefit from either an individual tele-education programme or standard care following the randomisation.
The psycho-education programme is based on 3 dimensions: educational (nature of the information and how it should be delivered), psychological (revelation of the diagnosis and transmission of information in a personalised way), behavioural and cognitive (restoring the skills and mobilising the resources of the subject in their daily functioning and in their relationship with the disease (management of treatment and communication skills in particular).
A low number of sessions has been chosen, as it is more appropriate for this population, whose disorders are not severe and who do not require specialist care. The emphasis was placed on personalising the information, with one-to-one sessions.
The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks.
The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment, in order to personalise the information to be provided about the programme.
The second session will focus on personalised hygienic and dietary measures. This will involve identifying sleep habits and leisure activities through behavioural analysis, and then identifying coping strategies with the patient in order to identify habits that can help combat depression.
A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed.
A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment.
The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent.
The liaison note is drawn up by the nurse with the patient for the general practitioner, focusing on: the patient's resources, in particular a personalised activity programme, and the patient's entourage, the areas of weakness identified and the risks identified of discontinuity in compliance.
Patients in the control group will receive standard care as usual. An educational booklet on depression, produced by the Institut National de Prévention et d'Education pour la Santé, will be sent to them by email after randomisation. It covers the symptoms, treatments and professionals to be consulted about depression. Patients will be able to consult this guide whenever they wish, without restriction, throughout the study.
Patients will usually be monitored by their General Practioner (GP), who may contact and refer them to the DSPP for psychiatric advice at any time during the study. The GP remains the referent for the patient's mental health care, with the support of the DSPP.
All participants in the study (control and experimental groups) may also be monitored by a psychologist, and will complete questionnaires.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Occitanie
-
Toulouse, Occitanie, France, 31000
- Recruiting
- CHU Toulouse
-
Contact:
- MARION LASSERRE, NURSE
- Phone Number: 05 61 77 60 41
- Email: lasserre.ma@chu-toulouse.fr
-
Contact:
- SOPHIE PREBOIS, MD
- Email: prebois.s@chu-toulouse.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Presenting a depressive episode of moderate intensity according to the Diagnostic and Statistical Manual (DSM)-V
- With a prescription for an antidepressant started less than 2 months before inclusion in the trial.
- Whose state of health is compatible with follow-up by their GP (possibility of occasional advice from a psychiatrist).
- Have Internet access at home (computer) and are able to use the digital platform.
Exclusion Criteria:
- Patients who are unable to complete self-questionnaires (language barrier, etc.)
- Who have already undergone a psycho-education or therapeutic patient education programme regarding depression.
- Whose state of health requires follow-up by a psychiatrist
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: psychoeducation program group
In addition to the usual treatment, the experimental group will receive a tele-education programme on depression in 5 individual remote sessions.
During these sessions, the symptoms of the illness will be discussed, as well as health and diet measures, the destigmatisation of the illness, mobilisation of family and friends, the various treatments for depression and, finally, an assessment of what has been learned, which will be sent to the general practitioner with the patient's agreement.
|
The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks. The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment. The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed. A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment. The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent. |
No Intervention: control group
The control group will receive their usual care from their GP.
An educational booklet on depression will be provided to patients at the start of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
medication adherence
Time Frame: 6 months post inclusion
|
The primary endpoint will be measured by the rate of maintenance on continuous antidepressant medication at 6 months after inclusion in the study. This maintenance rate will be measured using healthcare reimbursement data to reconstruct exposure to antidepressant medication at 6 months following inclusion in the study. |
6 months post inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of the tele-education
Time Frame: 3 months post inclusion
|
Effectiveness of the tele-education programme compared with usual care on : 1) Changes in feelings of self-efficacy using a scale of feelings of self-efficacy at inclusion and at 3 months: The investigators will use the General Self-Efficacy Scale (GSE). Each statement is scored from 1 to 4: "not at all true", "barely true", "moderately true" and "totally true". The scale contains ten items. This self-questionnaire will be completed by the patient via the digital platform at inclusion and 3 months post inclusion. |
3 months post inclusion
|
Effectiveness of the tele-education
Time Frame: 3 months post inclusion
|
Effectiveness of the tele-education programme compared with usual care on : 2) Changes in barriers to treatment using the Barriers to Care Evaluation (BACE) scale at inclusion and 3 months: The BACE-V3 scale is a self-administered questionnaire on barriers to access to care. It presents patients with possible barriers that may have prevented, delayed or discouraged them from seeking or pursuing professional care for a mental health problem. The help provided by a professional may be that of the GP, health staff (nurse, social worker, etc.), a psychiatrist, a counsellor, a psychologist or a psychotherapist. Patients are offered 4 response options for each of the 30 items, marked from 0 to 3: "not at all"; "a little"; "moderately"; "a lot". |
3 months post inclusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of depressive symptoms
Time Frame: 6 months post inclusion
|
Evolution of PHQ-9 depressive symptoms: This will be carried out by comparing the differences in scores on the PHQ-9 scale at inclusion and at 6 months. The Patient Health Questionnaire-9 (PHQ-9) is a validated tool for assessing the severity of depressive disorder. The PHQ9 is a self-report screening tool. It contributes to the overall assessment of the patient and to monitoring his or her progress. The PHQ9 has been widely used and validated in primary care. It comprises nine items and respondents are asked to rate their experience of nine common symptoms of depression over the past two weeks. It is a 4-point rating scale where 0 indicates "not at all" and 3 "always". No depression: score from 0 to 4, Mild depression: score from 5 to 9, Moderate depression: score from 10 to 14, Moderately severe depression: score from 15 to 19 Severe depression: score from 20 to 27. |
6 months post inclusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marion LASSERRE, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/22/0262
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Charite University, Berlin, GermanyCompletedTreatment Resistant Depression | Depression, Unipolar | Depression ChronicGermany
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
Clinical Trials on psychoeducative program
-
Institut Catala de SalutAgència d'Avaluació de Tecnologia i Recerca Mèdiques; Fundacio d'Investigacio...Unknown
-
Helsinki University Central HospitalCompletedFear of ChildbirthFinland
-
Nordsjaellands HospitalCompletedChronic Obstructive Pulmonary Disease | AnxietyDenmark
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedQuality of Life | MyositisSpain
-
Hospital San Juan de Dios del Aljarafe de SevillaUniversity of Seville; Fundación Pública Andaluza para la gestión de la Investigación...UnknownQuality of Life | Musculoskeletal Diseases | Chronic Pain | Pain MeasurementSpain
-
Ullevaal University HospitalThe Royal Norwegian Ministry of HealthCompletedDepression | Quality of Life | Breast Cancer | Anxiety | CopingNorway
-
Norwegian Institute of Public HealthUniversity of OsloCompleted
-
University of California, Los AngelesUniversity of California, San Francisco; Stanford University; California Initiative...Enrolling by invitationStress | Stress, Psychological | Stress, Emotional | Stress, Physiological | Stress ReactionUnited States
-
National Taiwan University HospitalCompleted